Utah Medical Products, Inc. — FY2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. The filing is an annual report; quarterly figures below identify the fourth quarter. Unless noted, amounts are in thousands of U.S. dollars.
Business context
UTMD develops, manufactures and sells specialized medical devices, primarily disposable products used in hospitals and women’s health, labor and delivery, and neonatal care. Its products are sold through direct channels, distributors and OEM relationships. International customers accounted for 53% of 2014 sales. Filshie Clip products represented 38% of total sales.
Financial results and liquidity
| Metric | 2014 | 2013 | Change or context |
|---|---|---|---|
| Net sales | $41,278 | $40,493 | +1.9% |
| Gross profit / margin | $24,983 / 60.5% | $24,273 / 59.9% | Profit +2.9%; margin +0.6 percentage points |
| Operating income / margin | $16,202 / 39.3% | $14,828 / 36.6% | Income +9.3% |
| Income before taxes | $15,812 | $14,476 | +9.2% |
| Net income | $11,378 | $11,406 | Nearly flat as reported |
| Diluted EPS | $3.02 | $3.02 | 2013 included a $0.976 million tax benefit |
| Operating cash flow | $15,387 | $12,308 | Strong cash generation |
| Cash and investments at year-end | $19,332 | $14,451 | Increase of approximately $4.9 million |
| Working capital / current ratio | $20,704 / 3.3 | $16,675 / 3.2 | Liquidity improved |
| Total liabilities / total assets | $16,520 / $81,076 | $20,130 / $80,711 | Debt ratio declined to 20% from 25% |
At December 31, 2014, notes payable totaled $4.867 million. UTMD repaid the remaining bank loan balances in February 2015 and reported that it was then debt-free. 2014 capital expenditures were $1.110 million; cash dividends paid were $3.765 million, and share repurchases were $1.055 million.
Fourth quarter: Sales were $10.243 million versus $10.085 million in Q4 2013; gross profit was $6.388 million versus $5.994 million. Net income was $3.000 million versus $3.468 million, and diluted EPS was $0.80 versus $0.92.
Material changes versus prior period
- Sales increased modestly, despite $1.183 million lower sales of blood-pressure-monitoring kits to the China distributor. Excluding those China sales, management said sales grew 5%.
- Operating income improved substantially as gross margin rose and operating expenses fell, notably following a change in the Australian sales and marketing model.
- Reported 2013 net income benefited from a one-time $976,000 reduction in tax expense following UK tax-rate changes affecting deferred taxes related to Femcare. Excluding that adjustment, 2014 net income and EPS increased about 9% versus 2013.
- International sales remained 53% of total sales. Gynecology/electrosurgery/urology revenue rose to $24.088 million, while obstetrics revenue declined to $4.669 million and blood-pressure-monitoring/accessories revenue declined to $6.299 million.
- Cash and current assets increased, while liabilities declined through debt repayment. Foreign-currency translation reduced other comprehensive income by $3.252 million in 2014.
Outlook, commentary and risks
Management’s 2015 outlook anticipated roughly flat organic sales in U.S.-dollar terms despite currency pressure. It projected gross margin of 58.5%–59.5%, operating margin of about 37%, pretax income of $14.9–$15.3 million, net income 3%–4% below 2014 and diluted EPS of $2.87–$2.92. These are management estimates, not guarantees. The company projected a stronger U.S. dollar could reduce reported sales by 2%–3% based on its assumed exchange rates; then-current rates could imply a larger impact.
- Principal risks include foreign-exchange exposure, regulatory approval costs and delays, U.S. medical-device excise tax and administrative burdens, hospital purchasing restrictions and GPO arrangements, competition, distributor dependence, product liability, and retention of skilled employees.
- Sales to the China distributor were volatile; management projected about $1.0 million of 2015 China blood-pressure-monitoring kit sales.
- Management said it was self-insured for product liability in the U.S. and Ireland; Femcare maintained third-party coverage. No litigation was pending at filing.
- There was no material weakness reported in internal control over financial reporting; management and the independent auditors reported effective controls. The financial statement audit opinions were unqualified.
- Management noted that cash held by foreign subsidiaries could trigger additional U.S. taxes if repatriated. It cited potential uses of cash including investment, acquisitions, dividends and repurchases.
Important facts for investors to verify
- Whether 2015 sales, margins and EPS tracked management’s projections, particularly after foreign-exchange movements.
- Whether Filshie Clip sales and the U.S. distributor relationship remain durable, given the product’s significant share of revenue.
- Whether sales recover or remain weak in U.S. labor-and-delivery products and China blood-pressure-monitoring kits.
- Whether cash generation, dividends and repurchases are sustainable alongside acquisition or investment plans, and how foreign cash repatriation would be treated.
- Whether the reported 2013 tax benefit and 2014 currency-related comprehensive-income loss are appropriately separated from recurring operating performance.